Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations

Background: Although superior clinical benefits of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer (NSCLC) had been reported with different sensitivity, the sensitivity of second-line TKIs in NSCLC patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhen, Jin, Xiance, Lin, Baochai, Su, Huafang, Chen, Hanbin, Fei, Shaoran, Zhao, Lihao, Deng, Xia, Xie, Deyao, Xie, Congying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370503/
https://www.ncbi.nlm.nih.gov/pubmed/28367239
http://dx.doi.org/10.7150/jca.16959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370503/
https://www.ncbi.nlm.nih.gov/pubmed/28367239
http://dx.doi.org/10.7150/jca.16959

Ejemplares similares